Market capitalization | $677.51m |
Enterprise Value | $400.65m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.57 |
P/S ratio (TTM) P/S ratio | 4.35 |
P/B ratio (TTM) P/B ratio | 1.38 |
Revenue growth (TTM) Revenue growth | 48.23% |
Revenue (TTM) Revenue | $155.90m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Fluidigm Corporation forecast:
3 Analysts have issued a Fluidigm Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 156 156 |
48%
48%
|
|
Gross Profit | 76 76 |
58%
58%
|
|
EBITDA | -103 -103 |
86%
86%
|
EBIT (Operating Income) EBIT | -120 -120 |
70%
70%
|
Net Profit | -125 -125 |
65%
65%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Michael Egholm |
Employees | 539 |
Founded | 1999 |
Website | www.standardbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.